RATIONALE: Adverse events (AEs) associated with sublingual immunotherapy (SLIT)-tablets used to treat allergic rhinoconjunctivitis and/or asthma occur at a rate of approximately 57%-83%, most of which are mildto-moderate. Biomarkers that could identify patients at risk of more severe reactions would be useful. Baseline specific IgE data from 11 trials of timothy grass, ragweed, house dust mite (HDM), and tree SLIT-tablets were evaluated for associations with frequency and severity of firstreported AEs. METHODS: Specific IgE (kUA/L) was divided into Class 0/1/2 (<3.5), Class 3 (3.5-17.4), Class 4 (17.5-49), Class 5 (50-99), or Class 6 (> _100). Patients' first-reported AEs were classified as none, mild, moderate, or severe. RESULTS: Overall, 9187 AEs were reported with SLIT-tablet treatment (n55298 patients). The percentages of patients with any AE were 51.7%, 62.4%, 64.4%, 64.9%, and 67.5% for baseline IgE Classes 0/1/2, Class 3, Class 4, Class 5, and Class 6, respectively. Most AEs were mild. The percentages of patients with moderate/severe AEs were slightly higher for Classes 5 (11.7%) and 6 (10.6%) versus lower Classes (5.1%-7.9%). Patterns of slightly increasing AE frequency with increasing IgE levels were observed for seasonal SLIT-tablets, whereas AE frequencies with HDM SLIT-tablet were comparable among IgE classes. AE frequency decreased over time, with approximately 80% of AEs occurring by week 5. CONCLUSIONS: The magnitude of baseline specific IgE corresponds with the frequency of AEs and appears to be a class effect of seasonal SLITtablets. The majority of AEs are mild and high IgE is not clearly associated with severe AEs. AE frequency decreases over time. However, the certification and recertification process is not widely practiced. Based on a hypothesis that SPT proficiency correlates with hands-on allergy experience, the objective was to gain insight into training requirements of staff and fellows in an academic practice. METHODS: Twenty allergy staff and physicians (9 RN, 2 NP, 9 MD/DO) used the QuintipÒ device to perform 10 repetitions of positive (histamine) and negative (diluent control) SPTs on the forearms, for practical purpose, after discontinuing antihistamines for a minimum of five days. Resulting orthogonal wheal diameters were recorded in mm in the presence of an independent observer. Mean histamine wheal diameters were used to determine SD. These values were used to calculate Coefficient of Variation (CV x1005CV%). Professional degree earned, postgraduate years, and years of hands-on allergy clinic experience were also documented. Prism GraphPad software was used for non-parametric Spearman correlation analyses. RESULTS: Seven subjects passed at the first attempt to achieve CV < 30% (median: 2; maximum: 3). Increased hands-on experience was associated with decreased histamine CV% (n 5 32, p5 0.0381). Subjects with less than 4 years of allergy experience as a group had wider variability of CV% (15.9-89.0%), regardless of professional degree. Intra-subject variability in one subject was 26% over 12 days. CONCLUSIONS: Hands-on experience in the allergy clinic inversely correlates with histamine CV%. This study highlights the importance of implementing systematic SPT proficiency certification and recertification. 1 Seoul National University College of Medicine, Seoul, Korea, Roza Khalmuratova, Seoul National University, Seoul, Korea, Republic of (South), 2 Boramae hospital, seoul, Korea, Republic of (South). RATIONALE: There is increasing evidence supporting the impact of neoosteogenesis in the pathophysiology of chronic rhinosinusitis (CRS), especially in the recalcitrant group of patients. Although Runt-related transcription factor 2 (Runx2), a member of Runx family, controls osteoblast differentiation and bone formation, the role and regulation of Runx2 in CRS with neo-osteogenesis patients remains unclear. METHODS: Sinonasal bone and overlying mucosa samples were obtained from patients with CRS with and without evidence of neoosteogenesis and healthy controls. Immunofluorescence, immunohistochemistry, and immunoblotting were performed to evaluate Runx2 expression in CRS patients with and without neo-osteogenesis. In addition, osteogenic capacity of proinflammatory cytokines were examined by alkaline phosphatase activity (ALP) and bone mineralization assay in vitro. RESULTS: Runx2 expression was increased in CRS patients with neoosteogenesis compared with tissue from control subjects and those with CRS without neo-osteogenesis (P<.01). Runx2 expression was detected in osteoblast cells around new bone surfaces in CRS sinonasal specimens. Moreover, mucosal extracts from CRS with neo-osteogenesis patients increased Runx2 expression in C2C12 cells, whereas those from patients without neo-osteogenesis did not. CONCLUSIONS: Taken together, thes findings suggest that Runx2 may regulate a new bone formation in CRS patients through its effect on the activity of osteoblasts. Thus Runx2 need to be considered as a novel target for preventing neo-osteogenesis in CRS patients.
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